Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Johnson & Johnson a Buy Now?

TheMotleyFool

0 0

Is Johnson & Johnson a Buy Now?: https://g.foolcdn.com/editorial/images/783645/investor-looking-at-charts-on-a-computer-with-light-reflecting-off-their-glasses.jpg

On July 17, Johnson & Johnson (NYSE: JNJ) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare conglomerate's needle forward for years to come.

Johnson & Johnson is made of many pieces that aren't moving in the same direction. Remicade, Imbruvica, and Zytiga are three blockbuster drugs in the company's pharmaceutical lineup that are losing ground to new competition.

Is Johnson & Johnson still a good dividend stock to buy? Let's weigh its strengths and opportunities against some challenges it faces to find out.

Source Fool.com

Like: 0

JNJ

Share